CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduced autologous T cells expressing anti-CD64 chimeric antigen receptors (CAR) expressing tandem CD3ζ and 4-1BB (CD3ζ/4-1BB) costimulatory domains in subjects with refractory or relapsed (R/R) acute myeloid leukemia (AML). This CAR T cell product will be referred to as "CD64 CAR T" which is CD64 directed, autologous, genetically modified CAR T cells. The primary objective of the study is to identify the safety profile and maximum tolerated

Trial Details

NCT ID

NCT07347418

Phase

PHASE1

Sponsor

University of Colorado, Denver

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• CD64 CAR T Cells

Locations (sample)

• Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

• ≥ 18 years of age.
• Subjects must have one of the following diagnoses per the International Consensus Classification (ICC) 2022 criteria:
• a. Acute Myeloid Leukemia (AML).
• Refractory OR relapsed AML:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →